Special Issue

Novel Approaches to Cancer Diagnosis and Therapy

Submission Deadline: 31 December 2021
Articles: 1
Special Issue Editor
Guest Editor
Dr. Yingqun Wang
BiomedSci, 1500 E Duarte RD, Duarte, CA 91010 USA
Expertise: Cancer Biology: 30 Publications, 3 Grants, Editor of Frontiers in Bioscience Special Issue: Cell cell Adhesion and Communications in Development and Tumorigenesis
Dr. Haihua Feng
City of Hope National Medical Center
Expertise: Cancer Biology; Biochemistry; DNA Damage/Repair; DNA Replication; Radiation Therapy
Special Issue Information

Dear Colleagues,

Early diagnosis, personalized treatment and biomarker-directed prognosis are the key components for the management of cancer patients. It has been well documented that the earlier the diagnosis is performed, the better will be the clinical outcome of cancer patients. Moreover, a thorough and accurate cancer diagnosis is the first step in developing an individualized cancer treatment plan. There are varieties of ways for cancer screening including physical exam, imaging test, blood test and biopsy. Although screening test can find tumors at its early stage, falsely positive or falsely negative screening test results remain a challenge for the doctors. A reliable diagnosis is essential for cancer therapy. Discovery of novel tumor biomarkers is an important way in the development of cancer diagnosis. The current next generation sequencing may provide instructions for cancer patient stratification and treatment plan decision. Moreover, the development of robust tumor cell-free circulating DNA screening in distinct cancer types is a promising method for early diagnosis of cancer.

Genetic and epigenetic alterations, which contribute to cancer cell growth, metastasis and escape from immunosurveillance, vary among patients. Especially, the complexity of genetic alteration of cancer cells poses a challenge in precise treatment for decades. The conventional cancer treatments such as surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy have improved the benefit of cancer patients, but many patients become resistant to these treatments and die from relapse. It is urgent to develop novel therapy strategies to increase therapeutic windows by reducing the side effects of current available cancer treatment modules. In particular, immunotherapy and oncolytic adenovirus vector based targeted therapy have shown promise in preclinical studies.

In this special issue we will bring experts in the field to communicate their findings on the development of novel approaches to cancer diagnosis and therapy. We hope that such efforts will contribute to better management of cancer patients in the clinic.

Dr. Yingqun Wang and Dr. Haihua Feng

Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at https://jour.ipublishment.com/bri by registering and logging into this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and written in clear, concise English and should contain all essential data in order to make the presentation clear and the results of the study replicable. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see


Cancer; Diagnosis; Therapy; Prognosis
Planned Paper(s)

Title: Targeting DNA Replication Fork for Cancer Therapy

Author: Changxian Shen

Title: Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy

Author: Lijun Mao

Title: Endoplasmic reticulum stress response in pancreatic cancer

Author: Xiaodong Tian

Share This Special Issue
Published Papers (1 papers)
Open Access

Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy

Chuang Wu, Fu-kun Wei, Zi-yang Xu, Ru-min Wen, Jia-cun Chen, Jun-qi Wang, Li-jun Mao
Frontiers in Bioscience-Landmark Volume 26 Issue 10, pp.866-872
Managing Editor: Graham Pawelec
DOI: 10.52586/4993 Published: 30 October 2021